OBiO Completes Shanghai IPO for Gene/Cell CDMO Services; Trades 67% Higher
publication date: Mar 22, 2022
OBiO Technology, a Shanghai CDMO for gene and cell therapies, completed an IPO on the Shanghai STAR Exchange and traded 67% higher on its first trading day, an unusually strong performance in the current market. The company did not disclose how much the offering raised. Founded in 2013, OBiO is a contract research organization for vectorology and functional genomics studies. It also provides contract development and manufacturing services of IND-enabling CMC, along with clinical and commercial manufacturing. To date, the company has supported more than 100 gene and cell therapy programs More details....
Stock Symbol: (SHA: 688238)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.